Overall, the identification of BTK and EPHA5 mutations in this patient’s tumor highlights the expanding landscape of genetic drivers in ovarian cancer and underscores the potential for using precision medicine to address previously unidentified mutation- driven pathways. Here, EPHA5 is linked to ovarian cancer.